Decheng Capital

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Decheng Capital, established in 2012 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Biotechnology, Health Care, Medical, Clinical Trials, Health Diagnostics, Financial Services, Venture Capital, Finance, Life Science, Genetics. The organization boasts a portfolio of 89 investments, with an average round size of $76.6M and 21 successful exits. Their recent investments include GeneWEAVE, Claremont Creek Ventures, XSeed Capital, Genapsys, IPV Capital. The highest investment round they participated in was $578.5B. Among their most notable exits are GeneWEAVE and Claremont Creek Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.